Sivakumar Vijayaraghavalu

Sivakumar Vijayaraghavalu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Naorem Loya MangangNaorem Loya Mangang
Naorem Loya Mangang
SGSamantha K Gargasz
Samantha K Gargasz
SMSai Ghanesh Murugan
Sai Ghanesh Murugan
MKMUNISH of KUMAR
MUNISH of KUMAR
GSGirish C Shukla
Girish C Shukla
SVSivakumar Vijayaraghavalu
Sivakumar Vijayaraghavalu
Cancer immunotherapy has transformed oncology, but lasting responses are still limited due to resistance mechanisms within the tumor microenvironment. MicroRNAs (miRNAs) have emerged as critical regulators of immune checkpoint pathways, antigen presentation, T-cell activity, and macrophage polarization. By modulating both tumor-intrinsic and immune cell–intrinsic processes, miRNAs influence the efficacy of immune checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapies. Additionally, circulating and exosomal miRNAs are being investigated as minimally invasive biomarkers to predict patient response and resistance to immunotherapy. Clinical trials of miRNA-based treatments, including mimics and inhibitors, have highlighted both the promise and challenges of translating these molecules into clinical use. Advances in delivery systems, RNA chemistry, and combinatorial strategies are paving the way for their integration into precision immuno-oncology. This review offers a comprehensive overview of the mechanistic, biomarker, and therapeutic roles of miRNAs in cancer immunotherapy, highlighting ongoing clinical progress and prospects.

Verified
Journal Article
Open access
PDF file
BLBorish Loushambam
Borish Loushambam
VKVenkateswaran Krishnaswami
Venkateswaran Krishnaswami
MKMUNISH of KUMAR
MUNISH of KUMAR
SVSivakumar Vijayaraghavalu
Sivakumar Vijayaraghavalu
Insulin injection remains the best therapy for diabetes mellitus, but subcutaneous injection continues to pose challenges, including patient discomfort, poor compliance and fluctuating plasma glucose profiles. Recently, transdermal insulin delivery has emerged as a non-invasive strategy that bypasses gastrointestinal degradation and first-pass hepatic metabolism, thereby increasing insulin bioavailability and enhancing patient acceptance. Recent developments in nanomedicine have facilitated the development of transdermal patches with enhanced drug encapsulation, uptake and controlled release. Nanostructured lipid carriers, polymeric nanocomposites, liposomes and SLNs have demonstrated a five-fold enhancement of transdermal flux and an extended insulin effect in preclinical models. The addition of ionic liquids and polymeric nanogels leads to an additional increase in insulin aqueous solubility and permeation, resulting from the temporary regulation of stratum corneum lipid organization. Bright and stimuli-responsive patches with glucose oxidase or phenylboronic acid functional groups enable regulated insulin delivery in response to changes in blood glucose, demonstrating near-normoglycemia for up to 48 h in animal testing. Nanocomposite systems assisted by microneedles have also been advanced to the early clinical phase, offering enhanced reproducibility of their pharmacokinetics and a low risk of dermal irritation. Despite these encouraging results, several translational challenges remain, such as biocompatibility, repeatability in the production of nanocarriers, long-term stability of formulations and regulatory standardization. This review examines the physicochemical design principles, materials innovations and permeation mechanism of nanomedicine-engineered insulin patches, the current state of preclinical and clinical advancements, challenges in production and future perspectives in viable patient-focused transdermal insulin delivery.

17 July 2026 in Archives of Cancer Biology and Therapy
Verified
Journal Article
Open access
PDF file
NMNaorem Loya Mangang
Naorem Loya Mangang
SVSivakumar Vijayaraghavalu
Sivakumar Vijayaraghavalu
MicroRNAs (miRNAs) have emerged as central regulators of antitumor immunity, influencing immune checkpoint signaling, immune cell differentiation, and intercellular communication within the tumor microenvironment. Although extensive preclinical evidence supports the immunomodulatory potential of miRNAs, their clinical translation remains challenging due to context dependence, network redundancy, delivery limitations, and safety concerns. Building upon recent advances in single-cell and spatial profiling, extracellular vesicle biology, and miRNA delivery technologies, this invited commentary critically examines how these developments extend current understanding of miRNA-mediated immune regulation in cancer. We highlight key conceptual and translational bottlenecks that continue to hinder therapeutic implementation and discuss why miRNAs are unlikely to achieve optimal efficacy as standalone immunotherapies. Instead, emerging evidence supports their greatest near-term clinical impact as adjunctive modulators and dynamic biomarkers within existing immunotherapeutic frameworks. By integrating mechanistic insights with translational perspectives, this commentary outlines future directions emphasizing cell-specific targeting, network-informed strategies, and biomarker-guided integration, providing a forward-looking framework for harnessing miRNAs in next-generation cancer immunotherapy.